Published in Infect Immun on November 01, 2001
Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun (2006) 1.63
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun (2005) 1.35
Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun (2006) 1.27
Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother (2004) 1.20
Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun (2003) 1.19
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol (2009) 1.18
Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog (2012) 1.18
The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol (2006) 1.16
Antibodies to the iron uptake ABC transporter lipoproteins PiaA and PiuA promote opsonophagocytosis of Streptococcus pneumoniae. Infect Immun (2005) 1.13
Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol (2009) 1.12
Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. Infect Immun (2006) 1.10
PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun (2009) 1.09
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clin Vaccine Immunol (2007) 1.05
Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS One (2010) 1.04
Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol (2007) 1.04
Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun (2004) 1.03
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun (2009) 0.99
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification. Mucosal Immunol (2010) 0.97
Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun (2006) 0.96
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol (2012) 0.95
Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine (2010) 0.94
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun (2002) 0.94
Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Infect Immun (2003) 0.91
Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol (2011) 0.87
Role of phosphoinositide 3-kinase-Akt signaling pathway in the age-related cytokine dysregulation in splenic macrophages stimulated via TLR-2 or TLR-4 receptors. Mech Ageing Dev (2011) 0.87
Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One (2013) 0.85
Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect Immun (2011) 0.85
A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation. J Virol (2004) 0.84
The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. Infect Immun (2012) 0.83
Mouse models for the study of mucosal vaccination against otitis media. Vaccine (2008) 0.83
Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice. Infect Immun (2003) 0.83
Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice. Clin Vaccine Immunol (2012) 0.81
Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly. Exp Gerontol (2014) 0.81
Construction and immunogenicity of recombinant adenovirus vaccines expressing the HMW1, HMW2, or Hia adhesion protein of nontypeable Haemophilus influenzae. Clin Vaccine Immunol (2010) 0.80
Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring. PLoS One (2011) 0.80
Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol (2011) 0.79
The host immune dynamics of pneumococcal colonization: implications for novel vaccine development. Hum Vaccin Immunother (2014) 0.79
Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine. PLoS One (2013) 0.77
Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. Clin Vaccine Immunol (2014) 0.76
Asthma and antibodies to pneumococcal virulence proteins. Infection (2013) 0.76
rIL-22 as an adjuvant enhances the immunogenicity of rGroEL in mice and its protective efficacy against S. Typhi and S. Typhimurium. Cell Mol Immunol (2014) 0.76
Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell (2014) 0.75
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice. Ther Adv Vaccines (2017) 0.75
A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia. J Infect Dis (2015) 0.75
A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly. Immune Netw (2015) 0.75
Immunization with Streptococcus suis bacterin plus recombinant Sao protein in sows conveys passive immunity to their piglets. BMC Vet Res (2017) 0.75
A combination of recombinant BCG expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol (2017) 0.75
Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol (1995) 10.65
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 5.50
T cell-independent antigens type 2. Annu Rev Immunol (1995) 4.62
Structure and function of human and murine receptors for IgG. Annu Rev Immunol (1988) 3.90
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol (1981) 2.11
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol (1997) 2.02
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine (1994) 1.96
Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol (1994) 1.92
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (1999) 1.84
Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol (1991) 1.81
Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol (1995) 1.68
The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine (2000) 1.48
GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature (1988) 1.45
Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol (1998) 1.44
IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol (1996) 1.42
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis (1999) 1.39
Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol (2000) 1.34
Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest (1999) 1.32
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol (2001) 1.31
Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis (2001) 1.30
Pneumococcal vaccines: history, current status, and future directions. Am J Med (1999) 1.25
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol (1998) 1.21
Biological function and distribution of human interleukin-12 receptor beta chain. Eur J Immunol (1996) 1.17
IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J Immunol (1996) 1.11
Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol (1997) 1.08
Defective antibody-mediated opsonisation of S. pneumoniae in high risk patients detected by flow cytometry. Immunol Lett (1996) 1.07
Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine (1999) 1.00
IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol (1998) 1.00
Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity. J Immunol (2001) 0.97
Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). J Infect Dis (2000) 0.95
Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int Immunol (1995) 0.94
Direct binding of IL-12 to human and murine B lymphocytes. Int Immunol (1996) 0.94
Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci (1996) 0.91
IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine (2001) 0.87
IgA-driven antibacterial activity against Streptococcus pneumoniae by mouse lung lymphocytes. Am Rev Respir Dis (1988) 0.83
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
Nucleotide sequence analysis of a gene encoding a streptomycin/spectinomycin adenylyltransferase. Plasmid (1985) 4.63
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis (1992) 3.52
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis (1999) 3.12
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Isolation and characterization of actinomycete antagonists of a fungal root pathogen. Appl Environ Microbiol (1993) 2.53
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol (2001) 2.47
Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog (1997) 2.41
Purification and some chemical and physical properties of staphylococcal enterotoxin A. Biochemistry (1972) 2.41
Anti-DNA autoantibodies in (NZB X NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotype. J Immunol (1982) 2.25
Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog (1994) 2.20
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun (1982) 2.19
Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature (1981) 2.16
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med Res Opin (2002) 2.04
The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol (1979) 2.02
A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun (1995) 2.01
Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine (2000) 2.00
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation (2001) 1.90
Human neutrophil-derived platelet activating factor. J Immunol (1980) 1.82
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selection. J Immunol (1989) 1.81
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol (2000) 1.78
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoid. Infect Immun (1985) 1.77
The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol (2001) 1.77
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol (1984) 1.72
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B Streptococcus pneumoniae. J Mol Evol (1998) 1.68
The use of colony development for the characterization of bacterial communities in soil and on roots. Microb Ecol (1994) 1.67
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
Phytotoxicity of acetic acid produced in the anaerobic decomposition of wheat straw. J Appl Bacteriol (1977) 1.67
Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog (1986) 1.64
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ther (2007) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Steroids and squalene in Methylococcus capsulatus grown on methane. Nature (1971) 1.60
Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA (1975) 1.56
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog (1997) 1.55
Inhibition of specific immune responses by feeding protein antigens. Int Arch Allergy Appl Immunol (1977) 1.54
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
Distinct functions of antigenic sites of the HN glycoprotein of Sendai virus. Virology (1987) 1.52
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol (1984) 1.48
Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics (1996) 1.46
Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol (1983) 1.45
A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cells. Microb Pathog (1992) 1.44
Inhibition of homocytotropic antibody responses in adult inbred mice by previous feeding of the specific antigen. J Allergy Clin Immunol (1977) 1.43
Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol (1987) 1.42
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Novel current-conducting composite substrates for exposing osteoblasts to alternating current stimulation. J Biomed Mater Res (2002) 1.40
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis (1999) 1.39
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog (1992) 1.39
A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog (1991) 1.35
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections. J Immunol (1985) 1.32
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol (2001) 1.31
Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis (2001) 1.30
Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization. J Immunol (1979) 1.29
Phagocytosis and killing of salmonella typhimurium by peritoneal exudate cells. Infect Immun (1981) 1.29
Pseudobacteremia caused by Clostridium sordellii. Arch Intern Med (1980) 1.29
Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol (1983) 1.27
Isoelectric focusing of immunoglobulins: improved methodology. J Immunol Methods (1980) 1.26
Sharing of an idiotypic marker by monoclonal antibodies specific for distinct regions of hen lysozyme. Nature (1980) 1.25
Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies. Microb Pathog (1988) 1.25
Impact of Field Release of Genetically Modified Pseudomonas fluorescens on Indigenous Microbial Populations of Wheat. Appl Environ Microbiol (1995) 1.25
Clonal dominance. I. Restricted nature of the IgM antibody response to group A streptococcal carbohydrate in mice. J Exp Med (1975) 1.24
Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun (1997) 1.24
Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun (2007) 1.23
Influence of resistance training volume and periodization on physiological and performance adaptations in collegiate women tennis players. Am J Sports Med (2001) 1.23
Development of a multi-specificity opsonophagocytic killing assay. Vaccine (2000) 1.22
The purification and characterization of the poison produced by Gonyaulax catenella in axenic culture. Biochemistry (1966) 1.22
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol (1998) 1.21
Physiological and performance responses to tournament wrestling. Med Sci Sports Exerc (2001) 1.20
Salmonella typhimurium virulence genes necessary to exploit the Itys/s genotype of the mouse. Infect Immun (1986) 1.20
A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog (1987) 1.18
Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee. J Infect Dis (2001) 1.18